Validation of PROMIS Banks With COPD Exacerbations
12 de diciembre de 2012 actualizado por: University of North Carolina, Chapel Hill
The Patient-Reported Outcomes Measurement Information System (PROMIS) is an NIH Roadmap initiative to develop a computerized system measuring patient-reported outcomes in respondents with a wide range of chronic diseases and demographic characteristics.
In the first four years of its existence, the PROMIS network developed item banks for measuring patient-reported outcomes in the areas of pain, fatigue, emotional distress, physical function, and social functioning.
During the item banking process, the PROMIS network conducted focus groups, individual cognitive interviews, and lexile (reading level) analyses to refine the meaning, clarity, and literacy demands of all items.
The item banks were administered to over 20,000 respondents and calibrated using models based on item response theory (IRT).
Using these IRT calibrations, computerized adaptive test (CAT) algorithms were developed and implemented.
The network has designed a series of studies using clinical populations to evaluate the item attributes, examine their utility as CATs, and validate the item banks.
More information on the PROMIS network can be found at www.nihpromis.org.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This is a prospective longitudinal study of adult patients with chronic obstructive pulmonary disease (COPD) who will be enrolled when their COPD is considered clinically stable or during an acute exacerbation. This design will allow both within-person and between-person comparisons by exacerbation experience. Comprehensive clinical and patient-reported assessments will be performed at baseline and at 3 months (end of study). Subsets of items will be administered by interactive voice response (IVR) over the course of the study to measure changes in key symptoms over the course of recovery from an exacerbation. A subset of patients will be interviewed at the end of the study to assess content validity of PROMIS items in this patient population.
With such a study design, we will be able to evaluate the validity of the PROMIS items in this patient population under acute and stable conditions and evaluate responsiveness of several PROMIS item banks under conditions of known change in an underlying chronic disease. We will also evaluate stability of sub-domains that are not hypothesized to change with COPD exacerbations.
Tipo de estudio
De observación
Inscripción (Actual)
188
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Illinois
-
Evanston, Illinois, Estados Unidos, 60201
- NorthShore University HealthSystem (Formerly Evanston Northwestern Healthcare)
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- University of North Carolina at Chapel Hill
-
Durham, North Carolina, Estados Unidos, 27701
- Duke University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15261
- University of Pittsburgh
-
Pittsburgh, Pennsylvania, Estados Unidos, 15240
- Pittsburgh VA Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
40 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
People presenting to primary care or specialty clinics with COPD either with exacerbation or without exacerbation.
People admitted to the hospital with a COPD exacerbation.
Descripción
Inclusion Criteria:
- An established clinical history of COPD in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition: COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
- A history of smoking (at least 10 pack/year history)
- Access to and able to communicate on a touch tone telephone
- Read and speak English
- Able to see and interact with a computer screen, mouse, and keyboard
- A signed and dated written informed consent prior to study participation
- For those enrolled into the exacerbation group: Treatment for an exacerbation may have been started no more than 3 days prior to the day of enrollment for patients recruited in the outpatient setting and no more than 6 days prior to the day of enrollment for patients recruited in the in-patients setting.
- For those enrolled in the stable state group, the patient will be considered stable if he or she has been exacerbation-free for a minimum of 2 months prior to enrollment.
Exclusion Criteria:
- Any concurrent medical or psychiatric condition that may preclude participation in this study or completion of self-administered questionnaires (e.g., moderate to severe dementia and/or severe, uncontrolled schizophrenia, or other condition that would render the participant unable to complete a questionnaire)
- History of asthma without co-existent COPD as the primary diagnosis
- Experiencing a current heart failure exacerbation. (A diagnosis of heart failure is not in itself an exclusion criterion.)
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Stable
Patients who are stable have not had a COPD exacerbation in the past 2 months.
|
|
Exacerbation
Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Darren A. Dewalt, MD, MPH, University of North Carolina, Chapel Hill
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de julio de 2008
Finalización primaria (Actual)
1 de junio de 2009
Finalización del estudio (Actual)
1 de junio de 2009
Fechas de registro del estudio
Enviado por primera vez
30 de octubre de 2008
Primero enviado que cumplió con los criterios de control de calidad
30 de octubre de 2008
Publicado por primera vez (Estimar)
2 de noviembre de 2008
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
13 de diciembre de 2012
Última actualización enviada que cumplió con los criterios de control de calidad
12 de diciembre de 2012
Última verificación
1 de diciembre de 2012
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 07-02
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .